Neonatal abstinence syndrome

New England Journal of Medicine

Volumn 375, Issue 25, 2016, Pages 2468-2479

  McQueen, Karen ^a   Murphy Oikonen, Jodie ^a  

^a LAKEHEAD UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; METHADONE; MORPHINE; PHENOBARBITAL;

BIOLOGIC TESTING; BREAST FEEDING; CALORIC INTAKE; CAUSE OF DEATH; CELLULITIS; CENTRAL NERVOUS SYSTEM DISEASE; CHAOTIC LIFESTYLE; CHILD HEALTH CARE; CHILD MALTREATMENT; CHILD PROTECTION; CHILD SAFETY; CHILDHOOD DISEASE; CLINICAL ASSESSMENT TOOL; CLINICAL FEATURE; DRUG ACTIVITY; DRUG HALF LIFE; ENDOCARDITIS; FINNEGAN NEONATAL ABSTINENCE SCORING TOOL; GASTROINTESTINAL DISEASE; HAIR ANALYSIS; HEAD CIRCUMFERENCE; HEALTH CARE; HEALTH PROGRAM; HEALTH PROMOTION; HEART DISEASE; HEPATITIS; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFANT NUTRITION; INFANT RISK; INTRAUTERINE GROWTH RETARDATION; LACTOSE FREE FORMULA; LIFESTYLE; LIPSITZ NEONATAL DRUG WITHDRAWAL SCORING SYSTEM; LONG TERM CARE; LOW BIRTH WEIGHT; MATERNAL HISTORY; MECONIUM; MEDICAL HISTORY; METABOLIC DISORDER; MOTHER CHILD RELATION; MOTHER NAS SCALE; NEONATAL ABSTINENCE SYNDROME; NEONATAL NARCOTIC WITHDRAWAL INDEX; NEONATAL WITHDRAWAL INVENTORY; OPIATE ADDICTION; OSTEOMYELITIS; OUTPATIENT CARE; PERIODIC LIMB MOVEMENT DISORDER; PREGNANT WOMAN; PREMATURE LABOR; PRIORITY JOURNAL; PROPHYLAXIS; RESPIRATORY TRACT DISEASE; REST; REVIEW; RISK FACTOR; ROOMING IN; SEPSIS; SEXUALLY TRANSMITTED DISEASE; SOCIAL SUPPORT; SOCIAL WORK; SOLUTIO PLACENTAE; SWADDLING; TOXICITY TESTING; UMBILICAL CORD BLOOD; URINALYSIS; VASOMOTOR DISORDER; VISUAL DISORDER; WEANING; WEIGHT GAIN; WEIGHT REDUCTION; COMPLICATION; FEMALE; NEWBORN; OPIATE SUBSTITUTION TREATMENT; PREGNANCY; PREGNANCY COMPLICATION;

FEMALE; HUMANS; INCIDENCE; INFANT, NEWBORN; METHADONE; MORPHINE; NEONATAL ABSTINENCE SYNDROME; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PREGNANCY; PREGNANCY COMPLICATIONS;

EID: 85007085354     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMra1600879     Document Type: Review

References (95)

1. Finnegan LP, Connaughton JF Jr, Kron RE, Emich JP. Neonatal abstinence syndrome: assessment and management. Addict Dis 1975;2:141-58.
2. Patrick SW, Kaplan HC, Passarella M, Davis MM, Lorch SA. Variation in treatment of neonatal abstinence syndrome in US children's hospitals, 2004-2011. J Perinatol 2014;34:867-72.
3. Kocherlakota P. Neonatal abstinence syndrome. Pediatrics 2014;134(2):e547-61.
4. Bagley SM, Wachman EM, Holland E, Brogly SB. Review of the assessment and management of neonatal abstinence syndrome. Addict Sci Clin Pract 2014;9:19.
5. Patrick SW, Schumacher RE, Benneyworth BD, Krans EE, McAllister JM, Davis MM. Neonatal abstinence syndrome and associated health care expenditures: United States, 2000-2009. JAMA 2012;307: 1934-40.
6. Patrick SW, Davis MM, Lehmann CU, Lehman CU, Cooper WO. Increasing incidence and geographic distribution of neonatal abstinence syndrome: United States 2009 to 2012. J Perinatol 2015;35:650-5.
7. Tolia VN, Patrick SW, Bennett MM, et al. Increasing incidence of the neonatal abstinence syndrome in U.S. neonatal ICUs. N Engl J Med 2015;372:2118-26.
8. Davies H, Gilbert R, Johnson K, et al. Neonatal drug withdrawal syndrome: cross-country comparison using hospital administrative data in England, the USA, Western Australia and Ontario, Canada. Arch Dis Child Fetal Neonatal Ed 2016; 101:F26-30.
9. Epstein RA, Bobo WV, Martin PR, et al. Increasing pregnancy-related use of prescribed opioid analgesics. Ann Epidemiol 2013;23:498-503.
10. Krans EE, Cochran G, Bogen DL. Caring for opioid-dependent pregnant women: prenatal and postpartum care considerations. Clin Obstet Gynecol 2015;58:370-9.
11. Stover MW, Davis JM. Opioids in pregnancy and neonatal abstinence syndrome. Semin Perinatol 2015;39:561-5.
12. Ailes EC, Dawson AL, Lind JN, et al. Opioid prescription claims among women of reproductive age - United States, 2008-2012. MMWR Morb Mortal Wkly Rep 2015;64:37-41.
13. Yazdy MM, Desai RJ, Brogly SB. Prescription opioids in pregnancy and birth outcomes: a review of the literature. J Pediatr Genet 2015;4:56-70.
14. Warren MD, Miller AM, Traylor J, Bauer A, Patrick SW. Implementation of a statewide surveillance system for neonatal abstinence syndrome - Tennessee, 2013. MMWR Morb Mortal Wkly Rep 2015;64:125-8.
15. Cicero TJ, Ellis MS, Harney J. Shifting patterns of prescription opioid and heroin abuse in the United States. N Engl J Med 2015;373:1789-90.
16. Gomes T, Juurlink DN. Opioid use and overdose: what we've learned in Ontario. Healthc Q 2016;18:8-11.
17. Jansson LM, Velez M. Neonatal abstinence syndrome. Curr Opin Pediatr 2012; 24:252-8.
18. Jumah NA. Rural, pregnant, and opioid dependent: a systematic review. Subst Abuse 2016;10:35-41.
19. Wong S, Ordean A, Kahan M, et al. Substance use in pregnancy. J Obstet Gynaecol Can 2011;33:367-84.
20. Patrick SW, Dudley J, Martin PR, et al. Prescription opioid epidemic and infant outcomes. Pediatrics 2015;135:842-50.
21. ACOG Committee on Health Care for Underserved Women, American Society of Addiction Medicine. ACOG committee opinion no. 524: opioid abuse, dependence, and addiction in pregnancy. Obstet Gynecol 2012;119:1070-6.
22. Visconti KC, Hennessy KC, Towers CV, Howard BC. Chronic opiate use in pregnancy and newborn head circumference. Am J Perinatol 2015;32:27-32.
23. Jansson LM, Velez ML. Infants of drugdependent mothers. Pediatr Rev 2011;32: 5-12.
24. Lee J, Hulman S, Musci M Jr, Stang E. Neonatal abstinence syndrome: influence of a combined inpatient/outpatient methadone treatment regimen on the average length of stay of a Medicaid NICU population. Popul Health Manag 2015;18:392-7.
25. O'Donnell M, Nassar N, Leonard H, et al. Increasing prevalence of neonatal withdrawal syndrome: population study of maternal factors and child protection involvement. Pediatrics 2009;123(4):e614-21.
26. Worley J. Identification and management of prescription drug abuse in pregnancy. J Perinat Neonatal Nurs 2014;28: 196-203.
27. Hudak ML, Tan RC, Committee on Drugs, Committee on Fetus and Newborn. Neonatal drug withdrawal. Pediatrics 2012;129(2):e540-60.
28. Jones HE, Kaltenbach K, Heil SH, et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med 2010;363:2320-31.
29. Brogly SB, Saia KA, Walley AY, Du HM, Sebastiani P. Prenatal buprenorphine versus methadone exposure and neonatal outcomes: systematic review and meta-analysis. Am J Epidemiol 2014;180:673-86.
30. Gawronski KM, Prasad MR, Backes CR, Lehman KJ, Gardner DK, Cordero L. Neonatal outcomes following in utero exposure to buprenorphine/naloxone or methadone. SAGE Open Med 2014;2: 2050312114530282.
31. Kaltenbach K, Jones HE. Neonatal abstinence syndrome: presentation and treatment considerations. J Addict Med 2016; 10:217-23.
32. Whiteman VE, Salemi JL, Mogos MF, Cain MA, Aliyu MH, Salihu HM. Maternal opioid drug use during pregnancy and its impact on perinatal morbidity, mortality, and the costs of medical care in the United States. J Pregnancy 2014;2014:906723.
33. Siu A, Robinson CA. Neonatal abstinence syndrome: essentials for the practitioner. J Pediatr Pharmacol Ther 2014;19: 147-55.
34. Newnam KM. The right tool at the right time: examining the evidence surrounding measurement of neonatal abstinence syndrome. Adv Neonatal Care 2014; 14:181-6.
35. D'Apolito KC. Assessing neonates for neonatal abstinence: are you reliable J Perinat Neonatal Nurs 2014;28:220-31.
36. Uebel H, Wright IM, Burns L, et al. Reasons for rehospitalization in children who had neonatal abstinence syndrome. Pediatrics 2015;136(4):e811-20.
37. Cleary BJ, Donnelly JM, Strawbridge JD, et al. Methadone and perinatal outcomes: a retrospective cohort study. Am J Obstet Gynecol 2011;204(2):139.e1-9.
38. Wachman EM, Newby PK, Vreeland J, et al. The relationship between maternal opioid agonists and psychiatric medications on length of hospitalization for neonatal abstinence syndrome. J Addict Med 2011;5:293-9.
39. Jansson LM, Garcia-Prats J, Kim S. Neonatal abstinence syndrome. UpToDate. August 3, 2016 (http://www.uptodate.com/ contents/neonatal-abstinence-syndrome# H17).
40. Wiles JR, Isemann B, Ward LP, Vinks AA, Akinbi H. Current management of neonatal abstinence syndrome secondary to intrauterine opioid exposure. J Pediatr 2014;165:440-6.
41. Kraft WK, Stover MW, Davis JM. Neonatal abstinence syndrome: pharmacologic strategies for the mother and infant. Semin Perinatol 2016;40:203-12.
42. Wachman EM, Hayes MJ, Brown MS, et al. Association of OPRM1 and COMT single-nucleotide polymorphisms with hospital length of stay and treatment of neonatal abstinence syndrome. JAMA 2013; 309:1821-7.
43. Smirk CL, Bowman E, Doyle LW, Kamlin COF. How long should infants at risk of drug withdrawal be monitored after birth J Paediatr Child Health 2014;50: 352-5.
44. Garcia AM. State laws regulating prescribing of controlled substances: balancing the public health problems of chronic pain and prescription painkiller abuse and overdose. J Law Med Ethics 2013;41: Suppl 1:42-5.
45. Krans EE, Patrick SW. Opioid use disorder in pregnancy: health policy and practice in the midst of an epidemic. Obstet Gynecol 2016;128:4-10.
46. Lendoiro E, González-Colmenero E, Concheiro-Guisán A, et al. Maternal hair analysis for the detection of illicit drugs, medicines, and alcohol exposure during pregnancy. Ther Drug Monit 2013;35:296- 304.
47. Narkowicz S, Potka J, Polkowska , Biziuk M, Namieœnik J. Prenatal exposure to substance of abuse: a worldwide problem. Environ Int 2013;54:141-63.
48. Clark L, Rohan A. Identifying and assessing the substance-exposed infant. MCN Am J Matern Child Nurs 2015;40(2): 87-95.
49. Kramlich D, Kronk R. Relational care for perinatal substance use: a systematic review. MCN Am J Matern Child Nurs 2015;40:320-6.
50. Wexelblatt SL, Ward LP, Torok K, Tisdale E, Meinzen-Derr JK, Greenberg JM. Universal maternal drug testing in a highprevalence region of prescription opiate abuse. J Pediatr 2015;166:582-6.
51. Cotten SW. Drug testing in the neonate. Clin Lab Med 2012;32:449-66.
52. Eichel MM, Johannemann TR. Implementation of universal maternal drug screening to identify neonatal abstinence syndrome candidates. Newborn Infant Nurs Rev 2014;14:17-22.
53. Murphy-Oikonen J, Montelpare WJ, Southon S, Bertoldo L, Persichino N. Identifying infants at risk for neonatal abstinence syndrome: a retrospective cohort comparison study of 3 screening approaches. J Perinat Neonatal Nurs 2010; 24:366-72.
54. Farst KJ, Valentine JL, Hall RW. Drug testing for newborn exposure to illicit substances in pregnancy: pitfalls and pearls. Int J Pediatr 2011;2011:951616.
55. Lozano J, García-Algar O, Vall O, de la Torre R, Scaravelli G, Pichini S. Biological matrices for the evaluation of in utero exposure to drugs of abuse. Ther Drug Monit 2007;29:711-34.
56. Orlando S. An overview of clinical tools used to assess neonatal abstinence syndrome. J Perinat Neonatal Nurs 2014; 28:212-9.
57. Jones HE, Seashore C, Johnson E, et al. Psychometric assessment of the Neonatal Abstinence Scoring System and the MOTHER NAS Scale. Am J Addict 2016; 25:370-3.
58. Lipsitz PJ. A proposed narcotic withdrawal score for use with newborn infants: a pragmatic evaluation of its efficacy. Clin Pediatr (Phila) 1975;14:592-4.
59. Green M, Suffet F. The Neonatal Narcotic Withdrawal Index: a device for the improvement of care in the abstinence syndrome. Am J Drug Alcohol Abuse 1981;8: 203-13.
60. Zahorodny W, Rom C, Whitney W, et al. The Neonatal Withdrawal Inventory: a simplified score of newborn withdrawal. J Dev Behav Pediatr 1998;19:89-93.
61. Maguire D, Cline GJ, Parnell L, Tai C-Y. Validation of the Finnegan Neonatal Abstinence Syndrome Tool-short form. Adv Neonatal Care 2013;13:430-7.
62. Dow K, Ordean A, Murphy-Oikonen J, et al. Neonatal abstinence syndrome clinical practice guidelines for Ontario. J Popul Ther Clin Pharmacol 2012;19(3):e488-506.
63. Jansson LM, Velez M, Harrow C. The opioid-exposed newborn: assessment and pharmacologic management. J Opioid Manag 2009;5:47-55.
64. Patrick SW. The triple aim for neonatal abstinence syndrome. J Pediatr 2015; 167:1189-91.
65. Velez ML, Jansson LM, Schroeder J, Williams E. Prenatal methadone exposure and neonatal neurobehavioral functioning. Pediatr Res 2009;66:704-9.
66. MacMullen NJ, Dulski LA, Blobaum P. Evidence-based interventions for neonatal abstinence syndrome. Pediatr Nurs 2014; 40:165-172, 203.
67. McQueen KA, Murphy-Oikonen J, Gerlach K, Montelpare W. The impact of infant feeding method on neonatal abstinence scores of methadone-exposed infants. Adv Neonatal Care 2011;11:282-90.
68. Welle-Strand GK, Skurtveit S, Jansson LM, Bakstad B, Bjarkø L, Ravndal E. Breastfeeding reduces the need for withdrawal treatment in opioid-exposed infants. Acta Paediatr 2013;102:1060-6.
69. Pritham UA, Paul JA, Hayes MJ. Opioid dependency in pregnancy and length of stay for neonatal abstinence syndrome. J Obstet Gynecol Neonatal Nurs 2012;41: 180-90.
70. Wachman EM, Schiff DM. Bringing attention to a need for a standardized treatment and weaning protocol for neonatal abstinence syndrome. Transl Pediatr 2016;5:12-5.
71. Reece-Stremtan S, Marinelli KA. ABM clinical protocol #21: guidelines for breastfeeding and substance use or substance use disorder, revised 2015. Breastfeed Med 2015;10:135-41.
72. McKnight S, Coo H, Davies G, et al. Rooming-in for infants at risk of neonatal abstinence syndrome. Am J Perinatol 2016;33:495-501.
73. Holmes AV, Atwood EC, Whalen B, et al. Rooming-in to treat neonatal abstinence syndrome: improved family-centered care at lower cost. Pediatrics 2016; 137(6):e1-9.
74. Tsai LC, Doan TJ. Breastfeeding among mothers on opioid maintenance treatment: a literature review. J Hum Lact 2016;32:521-9.
75. Newman A, Davies GA, Dow K, et al. Rooming-in care for infants of opioiddependent mothers: implementation and evaluation at a tertiary care hospital. Can Fam Physician 2015;61(12):e555-61.
76. Wachman EM, Byun J, Philipp BL. Breastfeeding rates among mothers of infants with neonatal abstinence syndrome. Breastfeed Med 2010;5:159-64.
77. Balain M, Johnson K. Neonatal abstinence syndrome: the role of breastfeeding. Infant 2014;10:9-13.
78. Lefevere J, Allegaert K. Question: is breastfeeding useful in the management of neonatal abstinence syndrome Arch Dis Child 2015;100:414-5.
79. Hall ES, Wexelblatt SL, Crowley M, et al. A multicenter cohort study of treatments and hospital outcomes in neonatal absti- nence syndrome. Pediatrics 2014;134(2): e527-34.
80. Jones HE, Fielder A. Neonatal abstinence syndrome: historical perspective, current focus, future directions. Prev Med 2015;80:12-7.
81. Grim K, Harrison TE, Wilder RT. Management of neonatal abstinence syndrome from opioids. Clin Perinatol 2013; 40:509-24.
82. Osborn DA, Jeffery HE, Cole MJ. Opiate treatment for opiate withdrawal in newborn infants. Cochrane Database Syst Rev 2010;10:CD002059.
83. Ohio Children's Hospitals Neonatal Research Consortium. Enternal morphine or methadone protocol for neonatal abstinence syndrome (NAS) from maternal exposure. August 22, 2013 (https://opqc.net/ sites/bmidrupalpopqc.chmcres.cchmc.org/ files/NAS/Ohio%20Childrens%20NAS% 20Treatment%20Protocol%200822%20 2013%20%20FINALrev2.pdf).
84. Patrick SW, Schumacher RE, Horbar JD, et al. Improving care for neonatal abstinence syndrome. Pediatrics 2016;137:1-8.
85. Wiles JR, Isemann B, Mizuno T, et al. Pharmacokinetics of oral methadone in the treatment of neonatal abstinence syndrome: a pilot study. J Pediatr 2015;167(6): 1214-20.e3.
86. Hall ES, Meinzen-Derr J, Wexelblatt SL. Cohort analysis of a pharmacokineticmodeled methadone weaning optimization for neonatal abstinence syndrome. J Pediatr 2015;167(6):1221-5.e1.
87. Kraft WK, Dysart K, Greenspan JS, Gibson E, Kaltenbach K, Ehrlich ME. Revised dose schema of sublingual buprenorphine in the treatment of the neonatal opioid abstinence syndrome. Addiction 2011;106:574-80.
88. Hall ES, Isemann BT, Wexelblatt SL, et al. A cohort comparison of buprenorphine versus methadone treatment for neonatal abstinence syndrome. J Pediatr 2016;170:39-44.e1.
89. Ng CM, Dombrowsky E, Lin H, et al. Population pharmacokinetic model of sublingual buprenorphine in neonatal abstinence syndrome. Pharmacotherapy 2015; 35:670-80.
90. Bio LL, Siu A, Poon CY. Update on the pharmacologic management of neonatal abstinence syndrome. J Perinatol 2011;31: 692-701.
91. Osborn DA, Jeffery HE, Cole MJ. Sedatives for opiate withdrawal in newborn infants. Cochrane Database Syst Rev 2010; 10:CD002053.
92. Streetz VN, Gildon BL, Thompson DF. Role of clonidine in neonatal abstinence syndrome: a systematic review. Ann Pharmacother 2016;50:301-10.
93. Kelly LE, Knoppert D, Roukema H, Rieder MJ, Koren G. Oral morphine weaning for neonatal abstinence syndrome at home compared with in-hospital: an observational cohort study. Paediatr Drugs 2015;17:151-7.
94. Liu A, Björkman T, Stewart C, Nanan R. Pharmacological treatment of neonatal opiate withdrawal: between the devil and the deep blue sea. Int J Pediatr 2011;2011: 935631.
95. Smirk CL, Bowman E, Doyle LW, Kamlin O. Home-based detoxification for neonatal abstinence syndrome reduces length of hospital admission without prolonging treatment. Acta Paediatr 2014; 103: 601-4.